FIRST WA.BIO.NEW DL-,0001FIRST WA.BIO.NEW DL-,0001FIRST WA.BIO.NEW DL-,0001

FIRST WA.BIO.NEW DL-,0001

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−2.02EUR
Revenue estimate
Market capitalization
‪5.19 M‬EUR
−77.9835EUR
‪−14.31 M‬EUR
‪1.95 M‬
Beta (1Y)
1.51

About First Wave BioPharma, Inc.

CEO
James E. Sapirstein
Headquarters
Boca Raton
Employees (FY)
9
Founded
2014
FIGI
BBG00F0XFGM7
First Wave Biopharma, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of non-systemic therapies for the treatment of gastrointestinal diseases. The firm is involved in a therapeutic development pipeline populated with multiple clinical stage programs built around its proprietary technologies, such as Niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its programs include FW-UP, FW-UC, FW-CD, FW-COV, FW-ICI-AC, MS1819, COVID-19 GI infections, and FW-EPI. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange FIRST WA.BIO.NEW DL-,0001 stocks are traded under the ticker 366.
FIRST WA.BIO.NEW DL-,0001 is going to release the next earnings report on May 20, 2024. Keep track of upcoming events with our Earnings Calendar.
366 earnings for the last quarter are −8.71 EUR per share, whereas the estimation was −10.60 EUR resulting in a 17.77% surprise. The estimated earnings for the next quarter are −4.47 EUR per share. See more details about FIRST WA.BIO.NEW DL-,0001 earnings.
Yes, you can track FIRST WA.BIO.NEW DL-,0001 financials in yearly and quarterly reports right on TradingView.
366 net income for the last quarter is ‪−3.72 M‬ EUR, while the quarter before that showed ‪−3.25 M‬ EUR of net income which accounts for −14.37% change. Track more FIRST WA.BIO.NEW DL-,0001 financial stats to get the full picture.
No, 366 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 366 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FIRST WA.BIO.NEW DL-,0001 stock right from TradingView charts — choose your broker and connect to your account.
366 reached its all-time high on Sep 24, 2018 with the price of 123900.0000 EUR, and its all-time low was 58.8000 EUR and was reached on Dec 27, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 30, 2024, the company has 9.00 employees. See our rating of the largest employees — is FIRST WA.BIO.NEW DL-,0001 on this list?
We've gathered analysts' opinions on FIRST WA.BIO.NEW DL-,0001 future price: according to them, 366 price has a max estimate of 32.88 EUR and a min estimate of 32.88 EUR. Read a more detailed FIRST WA.BIO.NEW DL-,0001 forecast: see what analysts think of FIRST WA.BIO.NEW DL-,0001 and suggest that you do with its stocks.